#1 Clinical Trials Search in Europe

Nmd670

NMD670 is an experimental drug currently being studied in clinical trials for various neuromuscular disorders. These trials aim to evaluate the safety, efficacy, and tolerability of NMD670 in patients with Myasthenia Gravis, Charcot-Marie-Tooth Disease, and Spinal Muscular Atrophy. The studies are designed to assess the drug’s potential benefits and side effects when administered over a 21-day period.

Table of Contents

What is NMD670?

NMD670 is a new experimental drug that is currently being studied for its potential to treat various neuromuscular disorders[1][2][3]. Neuromuscular disorders are conditions that affect the nerves that control voluntary muscles, leading to muscle weakness and other symptoms. While the exact mechanism of action of NMD670 is not explicitly stated in the available information, it appears to target the underlying causes of these disorders.

What conditions does NMD670 treat?

NMD670 is being investigated for the treatment of several neuromuscular conditions:

  • Myasthenia Gravis (MG): This is an autoimmune disorder that causes muscle weakness and fatigue. It can affect muscles that control eye and eyelid movement, facial expressions, chewing, swallowing, and breathing[1].
  • Charcot-Marie-Tooth Disease (CMT): This is a group of inherited disorders that cause nerve damage, leading to smaller, weaker muscles. It particularly affects the arms and legs[2].
  • Spinal Muscular Atrophy (SMA) Type 3: This is a genetic disorder affecting the part of the nervous system that controls voluntary muscle movement. Type 3 is a milder form that affects older children and adults[3].

How is NMD670 administered?

In all the clinical trials mentioned, NMD670 is administered as tablets taken twice a day for 21 days[1][2][3]. This suggests that it is an oral medication, which could be more convenient for patients compared to injections or infusions.

Current Clinical Trials

NMD670 is currently being studied in several Phase 2 clinical trials:

  • A Phase 2b trial for Myasthenia Gravis, testing three different dose levels[1].
  • A Phase 2a trial for Charcot-Marie-Tooth Disease types 1 and 2[2].
  • A Phase 2 trial for Spinal Muscular Atrophy Type 3[3].

These trials are all randomized, double-blind, and placebo-controlled, which means that participants are randomly assigned to either receive NMD670 or a placebo (a substance with no active ingredients). Neither the participants nor the researchers know who is receiving which treatment until the study is completed. This design helps ensure that the results are not influenced by expectations or bias.

How is NMD670’s effectiveness measured?

The effectiveness of NMD670 is being assessed using various measures specific to each condition:

  • For Myasthenia Gravis:
    • Quantitative Myasthenia Gravis (QMG) score: This measures the severity of MG symptoms. A lower score indicates improvement[1].
    • Myasthenia Gravis Activities of Daily Living (MG-ADL) score: This assesses how MG affects daily activities. A lower score indicates improvement[1].
    • Myasthenia Gravis Composite (MGC) score: Another measure of MG severity. A lower score indicates improvement[1].
    • Myasthenia Gravis Quality of Life 15 revised (MG-QOL15r) score: This measures the impact of MG on quality of life. A lower score indicates improvement[1].
  • For Charcot-Marie-Tooth Disease:
    • 6-minute walk test: This measures how far a person can walk in 6 minutes, assessing endurance and mobility[2].
    • 10-meter walk/run test: This measures how quickly a person can walk or run 10 meters, assessing speed and mobility[2].
    • Timed up-and-go test: This measures how quickly a person can stand up from a chair, walk a short distance, turn around, walk back, and sit down, assessing balance and mobility[2].
    • CMT Functional Outcome Measure: This assesses various aspects of function in CMT patients[2].
  • For Spinal Muscular Atrophy Type 3:
    • 6-minute walk test: As described above[3].
    • Muscle strength measurements: These assess the strength of various muscle groups[3].
    • Revised Hammersmith Scale (RHS): This measures motor function in SMA patients. A higher score indicates improvement[3].
    • Single fiber EMG measurements: These assess the function of individual muscle fibers and their connection to nerves[3].

Safety Monitoring

All three clinical trials are closely monitoring the safety of NMD670. This includes tracking[1][2][3]:

  • Adverse events (side effects)
  • Serious adverse events
  • Abnormalities in physical examinations
  • Changes in laboratory test results
  • Changes in vital signs
  • Changes in ECG (heart rhythm) readings
  • Any signs of suicidal thoughts or behavior
  • Changes in eye examinations

This comprehensive safety monitoring helps ensure that any potential risks of the medication are quickly identified and addressed.

Condition Study Phase Duration Primary Outcome Measures
Myasthenia Gravis Phase 2b 21 days Change in QMG total score
Charcot-Marie-Tooth Disease Phase 2a 21 days Change in 6-minute walk test, 10-meter walk/run test, timed-up-and-go test
Spinal Muscular Atrophy Type 3 Phase 2 21 days Change in 6-minute walk test total distance

FAQ

  • What is NMD670? NMD670 is an experimental drug being tested in clinical trials for various neuromuscular disorders. It is administered as tablets taken twice daily for 21 days in the current studies.
  • Which conditions are being studied with NMD670? NMD670 is being studied in clinical trials for Myasthenia Gravis, Charcot-Marie-Tooth Disease, and Spinal Muscular Atrophy Type 3.
  • How long do the clinical trials for NMD670 last? The current clinical trials for NMD670 involve a treatment period of 21 days, during which participants take the medication or a placebo twice daily.
  • What are the main outcomes being measured in these trials? The trials measure various outcomes, including changes in disease-specific scales, physical performance tests (like the 6-minute walk test), quality of life assessments, and safety parameters such as adverse events and laboratory abnormalities.
  • Are there any known side effects of NMD670? As NMD670 is still in clinical trials, its full side effect profile is not yet known. The studies are designed to monitor for any treatment-emergent adverse events, serious adverse events, and other safety parameters to assess the drug's safety profile.

Ongoing Clinical Trials on Nmd670

  • Study on the Safety and Effectiveness of NMD670 for Adults with Myasthenia Gravis

    Recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Belgium Denmark France Italy The Netherlands Poland +1

  • Study of NMD670 tablets to improve muscle strength in adults with Type 3 spinal muscular atrophy who can walk

    Not recruiting

    2 1
    Investigated drugs:
    Belgium Denmark Germany Italy The Netherlands Spain

  • Study on the Safety and Effectiveness of NMD670 for Adults with Charcot-Marie-Tooth Disease Types 1 and 2

    Not recruiting

    2 1
    Investigated drugs:
    Belgium Denmark France Spain

Glossary

  • Myasthenia Gravis: A chronic autoimmune disorder that causes muscle weakness and fatigue, particularly affecting the eyes, face, and throat muscles.
  • Charcot-Marie-Tooth Disease: A group of inherited disorders that affect the peripheral nerves, causing muscle weakness and loss of sensation in the legs, arms, hands, and feet.
  • Spinal Muscular Atrophy: A genetic disorder characterized by weakness and wasting in muscles used for movement, caused by a loss of specialized nerve cells in the spinal cord and brainstem.
  • Placebo: A substance with no active therapeutic effect, used as a control in clinical trials to compare against the experimental drug.
  • Double-Blind Study: A type of clinical trial where neither the participants nor the researchers know who is receiving the experimental treatment and who is receiving the placebo.
  • QMG Score: Quantitative Myasthenia Gravis Score, a scale used to measure the severity of Myasthenia Gravis symptoms.
  • 6-Minute Walk Test: A test that measures the distance an individual can walk in 6 minutes, used to assess physical performance and endurance.
  • ECG: Electrocardiogram, a test that records the electrical activity of the heart.
  • Adverse Event: Any unfavorable and unintended sign, symptom, or disease that occurs during a clinical trial, whether or not it is related to the treatment being studied.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.

References

  1. https://clinicaltrials.gov/study/NCT06414954
  2. https://clinicaltrials.gov/study/NCT06482437
  3. https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-nmd670-for-adults-with-type-3-spinal-muscular-atrophy/